Literature DB >> 35450815

Early-onset emphysematous pancreatitis indicates poor outcomes in patients with infected pancreatic necrosis.

Jiarong Li1, Chiayen Lin1, Caihong Ning1, Qin Wei1, Lu Chen1, Shuai Zhu1, Dingcheng Shen2, Gengwen Huang3.   

Abstract

BACKGROUND: Emphysematous pancreatitis (EP) is a subtype of infected pancreatic necrosis (IPN) characterized by presence of gas in (peri)pancreatic necrosis. However, the impacts of EP on outcomes of IPN are still controversial.
METHODS: A prospective database of consecutive patients with IPN in a tertiary hospital was post-hoc analyzed. Patients were assigned to EP and non-EP groups to perform a comprehensive comparison.
RESULTS: A total of 178 patients with IPN were enrolled and the overall mortality was 30.9%. EP accounted for 20.8% (n = 37) of cases and was significantly associated with higher incidences of Escherichia coli (45.9 versus 18.4%, P = 0.001) and Klebsiella pneumoniae (56.8 versus 33.3%, P = 0.009) infection. There was scarcely any disparity in clinical characteristics and outcomes between IPN patients with and without EP. However, patients with early-onset EP defined as air bubble signs occurring within 2 weeks from disease onset were significantly older and have higher prevalence of history of diabetes, and they were also associated with significantly higher mortality (57.1 versus 8.7%, P = 0.015) compared with late-onset patients.
CONCLUSIONS: The clinical outcomes of EP might be like those of non-emphysematous infection. However, when EP occurs within 2 weeks from disease onset, it is highly lethal.
Copyright © 2022. Published by Elsevier Ltd.

Entities:  

Keywords:  Emphysematous pancreatitis; Infected pancreatic necrosis; Outcomes

Year:  2022        PMID: 35450815     DOI: 10.1016/j.dld.2022.04.001

Source DB:  PubMed          Journal:  Dig Liver Dis        ISSN: 1590-8658            Impact factor:   4.088


  1 in total

1.  Massive emphysematous pancreatitis associated with duodenal microperforation.

Authors:  Michael van der Mark; Merwe Hartslief
Journal:  J Surg Case Rep       Date:  2022-09-14
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.